Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|LLY||Eli Lilly & Co.||-0.18%||370.42||1.1%||$1216.50m|
|JNJ||Johnson & Johnson||0.43%||178.76||0.7%||$1165.03m|
|MRK||Merck & Co., Inc.||-0.26%||109.83||0.7%||$1038.47m|
|BMY||Bristol-Myers Squibb Co.||0.74%||80.87||1.1%||$766.18m|
|HZNP||Horizon Therapeutics Plc||0.59%||100.88||5.4%||$307.91m|
|IDXX||IDEXX Laboratories, Inc.||3.12%||439.17||3.9%||$238.83m|
|NVO||Novo Nordisk A/S||1.22%||126.13||0.1%||$174.86m|
|ALNY||Alnylam Pharmaceuticals, Inc.||-0.15%||220.25||8.0%||$161.88m|
Akero Therapeutics, Inc. operates as a cardio-metabolic nonalcoholic steatohepatitis company, which engages in developing pioneering medicines designed to restore metabolic balance and improve overall health. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.